&w=3840&q=100)
Should you buy Biocon shares as USFDA gives approval to diabetes drug?
At 09:30 AM, Biocon shares were trading at ₹398.15, up by 1.97 per cent on the National Stock Exchange. In comparison, the Nifty50 witnessed a downtrend, trading at 25,140.05, down by 0.22 per cent or 55 points. So far this calendar year, shares of the biopharma company have experienced a decent rise of 6.8 per cent. Around 7.2 million shares have changed hands on the counter, cumulatively, on the NSE and BSE at the time of writing this report.
Kirsty has been available in the European Union (EU) and Canada since 2022. With the latest FDA approval, it becomes the first and only interchangeable biosimilar to NovoLog in the US. According to IQVIA data for 2024, Insulin Aspart US sales stood at $1.9 billion. This development marks Biocon Biologics' continued expansion spree in the diabetes portfolio.
About Kirsty
Kirsty is a rapid-acting insulin used to manage blood sugar levels in adults and children with diabetes. The insulin will be available in a prefilled pen for individual use and a multi-dose vial for both subcutaneous and intravenous usage.
'The FDA approval of Kirsty, the first and only interchangeable biosimilar rapid-acting Insulin Aspart in the US, is a significant step forward in our efforts to make insulin more accessible and affordable, said Shreehas Tambe, CEO and managing director, Biocon Biologics. "With Kirsty, we are expanding treatment choices for people living with diabetes and advancing our ambition to be a global leader in addressing unmet needs in diabetes care,' he added.
Brokerage View- WealthMills Securities
On an annual basis, Biocon shares have experienced a healthy double-digit rise of over 11 per cent on the bourses. Kranthi Bathini, director of equity strategy at WealthMills Securities, has maintained a 'Hold' rating on the stock. Biocon's future revenue growth will likely come from two main sources: its portfolio of biosimilars and new molecular entity.
The company is also planning to merge with its subsidiary firm, Biocon Biologics, to form business synergies. Just last month, the biopharma company raised ₹4,500 crore via a qualified institutional placement (QIP) issue.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
22 minutes ago
- India.com
Bharti Airtel hits massive JACKPOT, surpasses Tata's biggest company to become..., Mukesh Ambani's Reliance holds top spot, HDFC bank ranks...
Good news for Airtel users, now get Perplexity Pro AI annual subscription worth Rs 17000 for FREE, offer open to customers using..., here's how to claim it New Delhi: Bharti Airtel, one of India's largest telecom companies, has achieved a major milestone. According to the reports, Airtel has surpassed Tata Consultancy Services (TCS), the largest company of the Tata Group, to claim the third position in terms of market capitalization. Airtel's shares spiked by 1 percent, taking its market cap to Rs 11.45 lakh crore, which is over Rs 2,220 crore higher than that of TCS on Monday. Which company is at number one? Reliance Industries (RIL) is still the most valuable company in terms of market capitalization. The company owns a market capitalization of Rs 19.3 lakh crore. Reliance is followed by HDFC Bank with a market cap of Rs 15.3 lakh crore. Airtel has now replaced TCS to become the third most valuable company. Airtel's market capitalization has jumped by Rs 2 lakh crore this year. Here are some of the key details: Airtel has become the second-largest company in the Nifty50 after Reliance Industries. As for TCS, it has been facing a decline in market value. The drop in the market is attributed to weakness in the US markets and concerns related to AI. Reliance Industries (RIL) is still the most valuable company in terms of market capitalization. Reliance is followed by HDFC Bank with a market cap of Rs 15.3 lakh crore. Earlier, in 2009, Airtel had overtaken TCS, but at that time TCS was not in the third position. Several brokerage firms, including Jefferies, have given a bullish outlook on Airtel. They have described Airtel as an attractive investment option in light of India's growing consumption. Their estimate is that Airtel's earnings will continue to grow further, and its shares are likely to rise. It is important to note as of March 2025, Airtel had a total of 609.44 crore outstanding shares, including 39.23 crore partly-paid shares. So far this year, Airtel's shares have seen a 20.2 percent increase, while TCS shares have fallen by 22 percent.
Mint
2 hours ago
- Mint
Stocks to buy for long term: Pankaj Pandey of ICICI Securities recommends L&T, Lemon Tree Hotels, Dalmia Bharat and more
Stocks to buy for long term: The Indian stock market is reeling under pressure due to tariff blow by US President Donald Trump, uninspiring earnings and foreign capital outflow. The Nifty 50 is now over 7 per cent down from its all-time high of 26,277.35, which it hit on September 27 last year. At this juncture, it seems difficult to foresee a fresh high for the Nifty 50 in the near future. Trump's tariffs are estimated to reduce India's GDP growth by as much as 1 per cent, hopes of an earnings recovery in the second half of the financial year (H2FY26) are weakening, and foreign investors are relentlessly pulling money out of Indian markets. Pankaj Pandey, the head of research at ICICI Securities, still believes that the Indian stock market can emerge from the Trump tariffs shock and the Nifty may hit the 27,000 level by the end of the year. "On an overall basis, we see limited impact on the equity market amid the India-US tariff across most sectors. We, in fact, see current tariff threats as negotiation tactics," said Pandey. Pandey even sees some winners out of this trade war. For example, with tariffs being imposed by the US across countries, India's relative export competitiveness has improved at the global stage in the electronic manufacturing service (EMS) segment, he explained. The head of research at ICICI Securities underscored that the trade war is still an evolving space, but it will force global brands to look for alternatives to countries like China over the medium term for manufacturing electronics items like mobile phones and laptops. However, Pandey said the contours of the ultimate tariff, which will be clear later once the negotiations end, will hold the key. "We believe we have learnt to live with this uncertainty and domestic factors such as corporate earnings, as well as macroeconomic indicators like GDP growth, capex spending, consumption, etc, will be a bigger catalyst," said Pandey. "Overall, we expect markets to move towards a new high by FY26 end. Our 12-month rolling Nifty target is pegged at 27,000 levels, wherein we have valued the index at nearly 22 times PE on FY27E," Pandey said. Larsen & Toubro (L&T) is India's largest engineering and construction (E&C) company. It has a current order backlog of ₹ 6,12,761 crore. L&T began FY26 with a strong quarter at 16 per cent revenue growth and 33 per cent growth in order inflows. L&T further has ₹ 14.8 lakh crore order bid pipeline for the remaining nine months of the financial year (9MFY26E). "With solid execution momentum expected to continue, we expect revenues and PAT to grow at a CAGR of 14.5 per cent and 19.4 per cent over FY25-FY27E. Further, L&T aspires to reach 18 per cent ROE by FY26E versus nearly 17 per cent in Q1FY26 and is best placed to play the India capex-led growth story," said Pandey. City Union Bank is a strong regional franchise with a deep-rooted presence in South India. Nearly 56 per cent of its advances are in secured MSME and agri segments. City Union Bank is well-positioned to deliver advanced growth surpassing the industry, aided by its focus on high-yield, granular segments. Margins are expected to remain resilient in the range of 3.45–3.5 per cent despite repo-linked repricing, supported by a favourable loan mix and improved liabilities mobilisation. Credit costs are projected to stay benign at nearly 50–60 bps, with an aim to raise specific PCR to nearly 63–64 per cent. While MSME stress remains a key monitorable, better-than-peer margins, stable asset quality and RoA at 1.4-1.5 per cent, justify relatively superior valuation. Lemon Tree Hotels is emerging as India's largest hotel chain in the mid-priced sector, with a room inventory of 10,269 in 111 hotels. 'Scale-up in performance of Aurika Mumbai and strong growth of 40 per cent+ in management contract revenues, coupled with steady growth in existing hotels, will drive Revenue and PAT CAGR of 16 per cent and 33 per cent over FY25-27E,' said Pandey. Value unlock in its subsidiary Fluer will be an additional trigger for stock, along with favourable industry tailwinds. Dalmia Bharat, the fourth largest cement manufacturer in India with a cement capacity of 49.5 mtpa, is poised to grow significantly, led by capacity additions along with a strong focus on capital allocation and cost-saving measures. With ongoing expansions at Karnataka, Maharashtra & Andhra Pradesh (3 mtpa each), total capacity would reach 61.5 mtpa by FY28E. Company targets to reach 110-130 mtpa by FY31E. "Profitability to improve driven by operational efficiencies (led by increasing green power share, optimisation of fuel mix, logistics, etc.) and positive operating leverage, translating to nearly 30 per cent EBITDA CAGR over FY25-27E," said Pandey. Steel Strips Wheels is a prominent player in the domestic oligopolistic wheels industry. It currently has five plants in India with a total production capacity of nearly 2.5 crore wheels per annum (including nearly 0.42 crore of alloy wheels), and it realises 32 per cent of its revenue from alloy wheels. "Its powertrain agnostic product profile (no EV risk) and healthy growth in volumes supported by capacity expansion will help it to achieve sales and PAT CAGR of 10 per cent and 17 per cent, respectively, over FY25P-27E," Pandey observed. "It is one of the inexpensive stocks in the auto ancillary space and trades at less than 13 times PE on FY27E, offering healthy upside. Double-digit CFO yield provided a good margin of safety," Pandey said. Read all market-related news here Read more stories by Nishant Kumar Disclaimer: This story is for educational purposes only. The views and recommendations expressed are those of the expert, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.
India Today
2 hours ago
- India Today
Vinay Prasad returns as US vaccine regulator chief days after stepping down
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the US Food and Drug Administration a little more than a week after he left the agency."At the FDA's request, Dr Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research," US Health and Human Services spokesperson Andrew Nixon said in an emailed statement to left the agency on July 30 after just a few months as director of the center. Endpoints News first reported the return of an oncologist who was a fierce critic of US COVID-19 vaccine and mask mandates, was named the center's director by FDA Commissioner Marty Makary in of Prasad's tenure intensified around the agency's handling of a gene therapy for Duchenne muscular dystrophy from Sarepta Therapeutics FDA-approved therapy played a role in the death of two teens who had advanced DMD. After a third death in a separate experimental gene therapy from the company, the FDA asked Sarepta on July 18 to stop all shipments of the approved DMD therapy, saying it had safety FDA changed course on Sarepta on July 28 and said shipments to the main group of patients for the drug could Loomer, a far-right activist and an ally of US President Donald Trump, posted a blog on July 20 in which she called Prasad a "progressive leftist saboteur" who was undermining the agency's was a physician who joined the agency from the University of California, San Francisco. He has had stints at the National Cancer Institute and the National Institutes of FDA and other health agencies have seen multiple shake-ups in recent months under the leadership of US Health Secretary Robert F Kennedy Jr.- Ends
